NASDAQ$TOI
Oncology Institute Inc/The · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Reported strong financial results driven by growth in patient services and strategic partnerships.
The Oncology Institute announced strong financial results for Q2 2024, marked by a significant increase in revenue and EPS. The company's growth was fueled by expanded patient services and successful strategic partnerships, positioning it for continued success in the oncology market.
- Revenue increased significantly due to expanded patient services.
- Earnings per share (EPS) exceeded expectations.
- Strategic partnerships drove growth and market penetration.
- The company is well-positioned for continued growth in the oncology market.
Headline financials
Revenue & EPS history
Oncology Institute · Revenue · Quarterly
$98.6M
Revenue by segment
Oncology Institute · $82M total across 3 segments · Q3 2023
- Patient Services$53.6M+20.2%65.4%
- Dispensary$26.8M+42.2%32.7%
- Clinical Trials & Other$1.61M—2.0%
Forward guidance
The Oncology Institute anticipates continued growth in the next quarter, driven by ongoing expansion of patient services and strategic partnerships. The company expects to maintain strong financial performance and further penetrate the oncology market.
Tailwinds
- Continued expansion of patient services.
- Further development of strategic partnerships.
- Strong financial performance expected to continue.
- Increased market penetration in oncology.
- Positive outlook for revenue and EPS growth.
Headwinds
- Potential challenges from increased competition.
- Risk of changes in healthcare regulations.
- Uncertainties in the global economic environment.
- Possible delays in new treatment approvals.
- Impact of rising operating costs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
+2.6%
Avg return
Earnings day
+2.7%
Avg return
5 days after
+8.0%
Avg return
30 days after
62%
13 / 21 earnings
Positive
+28.9%
Q3 2025
Best reaction
-23.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +6.8% | +5.8% | +27.9% | |
| Q4 2025 | +8.4% | +37.4% | +17.6% | |
| Q3 2025 | +28.9% | +6.2% | +22.7% | |
| Q1 2025 | +28.3% | +17.3% | +4.2% | |
| Q4 2024 | +24.5% | +14.5% | +189.2% | |
| Q3 2024 | -23.4% | -43.8% | -5.1% | |
| Q2 2024 | -20.4% | -11.1% | -26.9% | |
| Q1 2024 | +3.6% | -26.5% | -46.6% | |
| Q4 2023 | +8.9% | -7.7% | -32.0% | |
| Q3 2023 | +5.7% | +46.6% | -27.6% | |
| Q2 2023 | -10.1% | -13.3% | +28.3% | |
| Q1 2023 | +4.2% | -6.3% | +29.2% | |
| Q4 2022 | +1.9% | -5.8% | -30.6% | |
| Q3 2022 | -4.3% | -35.5% | -66.4% | |
| Q2 2022 | +0.6% | -1.2% | -9.6% | |
| Q1 2022 | -14.7% | -11.8% | -6.5% | |
| Q2 2021 | +10.3% | +31.4% | +48.1% | |
| Q4 2020 | +10.3% | +31.4% | +48.1% | |
| Q4 2021 | -14.6% | +18.5% | +26.5% | |
| Q3 2021 | +0.0% | +10.0% | -23.6% | |
| Q1 2021 | -0.2% | +1.0% | +0.7% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro